• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.

作者信息

Gordon Max J, Raess Philipp W, Young Kathleen, Spurgeon Stephen E F, Danilov Alexey V

机构信息

Department of Medicine, Oregon Health and Science University, Portland, OR, USA.

Department of Pathology, Oregon Health and Science University, Portland, OR, USA.

出版信息

Br J Haematol. 2017 Nov;179(3):501-503. doi: 10.1111/bjh.14224. Epub 2016 Jul 8.

DOI:10.1111/bjh.14224
PMID:27391978
Abstract
摘要

相似文献

1
Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.伊布替尼是治疗B细胞原淋巴细胞白血病的一种有效疗法。
Br J Haematol. 2017 Nov;179(3):501-503. doi: 10.1111/bjh.14224. Epub 2016 Jul 8.
2
What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.老年慢性淋巴细胞白血病患者的标准一线治疗应该是什么？依鲁替尼应作为标准一线治疗。
Clin Adv Hematol Oncol. 2016 May;14(5):330-3.
3
Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.依鲁替尼用于日本复发/难治性套细胞淋巴瘤患者的II期研究的最终分析。
J Clin Exp Hematop. 2019;59(2):98-100. doi: 10.3960/jslrt.19006.
4
Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.伊布替尼单药治疗复发/难治性双表达 B 细胞淋巴瘤患者的结局。
Blood Adv. 2019 Jan 22;3(2):132-135. doi: 10.1182/bloodadvances.2018026401.
5
Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.依鲁替尼是一种治疗累及中枢神经系统的系统性套细胞淋巴瘤的安全有效的疗法——来自英国的一项多中心病例系列研究。
Br J Haematol. 2017 Jul;178(2):327-329. doi: 10.1111/bjh.14122. Epub 2016 May 16.
6
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.伊布替尼治疗复发/难治性慢性淋巴细胞白血病的老年患者：法国71例患者的真实世界经验：法国创新白血病组织（FILO）组的一项研究
Am J Hematol. 2017 Jun;92(6):E105-E107. doi: 10.1002/ajh.24715. Epub 2017 Apr 29.
7
Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.依鲁替尼治疗的慢性淋巴细胞白血病患者中的进行性多灶性白质脑病
Br J Haematol. 2018 Jan;180(2):301-304. doi: 10.1111/bjh.14322. Epub 2016 Sep 21.
8
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.一线伊布替尼治疗老年慢性淋巴细胞白血病患者的持续疗效和详细临床随访：RESONATE-2 扩展阶段 3 的结果。
Haematologica. 2018 Sep;103(9):1502-1510. doi: 10.3324/haematol.2018.192328. Epub 2018 Jun 7.
9
Ibrutinib is Effective in Refractory Type II Cryoglobulinemia.伊布替尼对难治性Ⅱ型冷球蛋白血症有效。
Clin Lymphoma Myeloma Leuk. 2019 Dec;19(12):e629-e632. doi: 10.1016/j.clml.2019.07.442. Epub 2019 Sep 3.
10
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.伊布替尼用于复发/难治性慢性淋巴细胞白血病：英国和爱尔兰315例患者的疗效分析。
Haematologica. 2016 Dec;101(12):1563-1572. doi: 10.3324/haematol.2016.147900. Epub 2016 Oct 18.

引用本文的文献

1
Zanubrutinib as Upfront Treatment in de Novo B-Cell Prolymphocytic Leukemia: The Case of Two Elderly Patients.泽布替尼作为初治新发B细胞幼淋巴细胞白血病的治疗方法：两名老年患者的病例
Mediterr J Hematol Infect Dis. 2025 Sep 1;17(1):e2025061. doi: 10.4084/MJHID.2025.061. eCollection 2025.
2
Prolymphocytic Leukaemia: an Update on Biology and Treatment.慢性淋巴细胞白血病：生物学和治疗的最新进展。
Curr Oncol Rep. 2024 Feb;26(2):129-135. doi: 10.1007/s11912-023-01485-3. Epub 2024 Jan 2.
3
An effective treatment and suspicious adverse reaction to Ibrutinib in a patient diagnosed with splenic B-cell lymphoma/leukaemia with prominent nucleoli: A first case report.
1 例伴有明显核仁的脾 B 细胞淋巴瘤/白血病患者伊布替尼的有效治疗及可疑不良反应：首例报告。
Medicine (Baltimore). 2023 Dec 29;102(52):e36022. doi: 10.1097/MD.0000000000036022.
4
Retrospective analysis of a cohort of 41 B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study).41例B细胞幼淋巴细胞白血病患者队列的回顾性分析：遗传学和靶向治疗的影响（一项FILO研究）
Haematologica. 2023 Jun 1;108(6):1691-1696. doi: 10.3324/haematol.2022.282162.
5
Zanubrutinib, rituximab and lenalidomide induces deep and durable remission in TP53-mutated B-cell prolymphocytic leukemia: a case report and literature review.泽布替尼、利妥昔单抗和来那度胺可诱导TP53突变的B细胞原淋巴细胞白血病获得深度且持久的缓解：一例病例报告及文献综述
Haematologica. 2022 May 1;107(5):1226-1228. doi: 10.3324/haematol.2021.280259.
6
How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen.如何诊断和治疗累及脾脏的 CD5 阳性淋巴瘤。
Curr Oncol. 2021 Nov 11;28(6):4611-4633. doi: 10.3390/curroncol28060390.
7
Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax.伊布替尼和维奈托克治疗伴有17p缺失和TP53突变的B细胞原淋巴细胞白血病实现持续微小残留病阴性缓解
Leuk Res Rep. 2021 Aug 30;16:100266. doi: 10.1016/j.lrr.2021.100266. eCollection 2021.
8
An illustrative case of B-cell prolymphocytic leukemia.B细胞幼淋巴细胞白血病的一个典型病例。
Blood Res. 2020 Sep 30;55(3):181-184. doi: 10.5045/br.2020.2020079.
9
Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion.序贯激酶抑制（idelalisib/依鲁替尼）可诱导携带17p缺失的B细胞幼淋巴细胞白血病出现临床缓解。
Case Rep Hematol. 2017;2017:8563218. doi: 10.1155/2017/8563218. Epub 2017 Jul 27.